無料プレビュー

Celldex Therapeutics, Inc. (CLDX) · NASDAQ Capital Market

プロフィール

Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibodies targeting mast cell biology to treat inflammatory, allergic, and autoimmune diseases. Its lead candidate, barzolvolimab (CDX-0159), a KIT receptor antagonist, is in Phase 3 trials for chronic spontaneous urticaria, chronic inducible urticaria, and earlier stages for prurigo nodolaris and atopic dermatitis. Its pipeline includes CDX-622, a bispecific antibody targeting TSLP and SCF for inflammatory diseases in Phase 1 development. Celldex operates as a research and development organization with m

主要指標

株価: $29.56 (+0.89%)
時価総額: 20億ドル
PER（今期予想）: -7.2
PBR: 3.2
配当利回り: —
52週レンジ: $22.10 – $45.14
業種: Healthcare / Biotechnology
上場: NASDAQ Capital Market
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、RVMD Revolution Medicines, Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-09 · 更新: 2026-10-09